Cardiology

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Q&A, Exercise, Patient, Pulmonary hypertension, Cardiovascular Research, Clinical trial, IP, Therapy, LINK, Research, Science, LEVEL, Public expenditure, Heart failure, Development, Tenax, Disease, KOL, TNX-102, First, Research and development, MPH, Cardiology, Conference, Patent, Doctor of Philosophy, Faculty, MBA, Levosimendan, THT, Feinberg School of Medicine, Pharmaceutical industry

We also made important progress in further expanding levosimendan’s U.S. intellectual property protections, securing the future commercial value of TNX-103.

Key Points: 
  • We also made important progress in further expanding levosimendan’s U.S. intellectual property protections, securing the future commercial value of TNX-103.
  • In February 2024, Tenax Therapeutics announced that the first patient had enrolled in the Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ).
  • LINK TO REGISTER
    Tenax Therapeutics reported cash and cash equivalents of $9.8 million as of December 31, 2023.
  • Tenax Therapeutics reported a net loss for 2023 of $7.7 million, compared to a net loss of $11.0 million in 2022.

InfoBionic Rebrands Company Name to ‘InfoBionic.Ai’, Reinforcing Focus on AI-Enabled ECG

Retrieved on: 
Tuesday, April 9, 2024
Technology, Medical Devices, Health Technology, Telemedicine, Virtual Medicine, Cardiology, Software, Other Health, General Health, Health, Artificial Intelligence, Intelligence, ARC, Machine learning, Mayo Clinic, FDA, Heart, ECG, AI, Medical device

InfoBionic has always been dedicated to remaining at the cutting edge of patient care.

Key Points: 
  • InfoBionic has always been dedicated to remaining at the cutting edge of patient care.
  • Since the organization’s inception in 2015, AI and machine learning have been an integral part of InfoBionic’s remote cardiac telemetry offering.
  • In reality, this name change is just formalizing what we have already become,” says Stuart Long, CEO of InfoBionic.Ai.
  • “Our commitment to evolving remote cardiac telemetry monitoring through existing and novel AI-enabled ECG remains steadfast and unwavering.

HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

Retrieved on: 
Tuesday, April 9, 2024
Technology, Medical Devices, Health Technology, Cardiology, Software, Biotechnology, Health, Data Management, Artificial Intelligence, Algorithm, Atrial flutter, Intelligence, Patient, Doctor of Philosophy, MD, Arrhythmia, Vectorcardiography, FDA, VCG, ECG, Medical device

This marks the first scientific presentation on the company’s deep learning algorithm, HeartBeam AI.

Key Points: 
  • This marks the first scientific presentation on the company’s deep learning algorithm, HeartBeam AI.
  • The technology is designed to be used in HeartBeam’s small, portable, patient-friendly devices that allow for remote cardiac monitoring.
  • HeartBeam believes this presents a unique opportunity to create a comprehensive repository of data that could unlock personalized AI-driven insights to improve cardiac care.
  • “As we continue to expand our artificial intelligence capabilities, we look forward to demonstrating how the combination of our data rich 3D VECG platform with HeartBeam AI has the potential to transform how cardiac health is managed in the future.”

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

Retrieved on: 
Tuesday, April 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Tobacco, Clinical Trials, Retail, Disease, Cardiovascular Research, Society, IND, Psychology, Therapy, Senior counsel, Population health, School, Dean (education), Partnership, Nicotine, Policy, Smoker, Behavior, NIH, Brown University, Trial of the century, University, SAB, Pharmacology, Homelessness, San Francisco General Hospital, UCSF, Public, Cancer, MD, Publication, Heated tobacco product, Hospital, Juul, FDA, Alpert Medical School, Pregnancy, Chair, Public health, University of Kansas, Cardiology, CTA, Mortality, Louisiana State University, Doctor of Philosophy, MHRA, Smoking, Toxicology, Division, Brown, Social science, Pharmaceutical industry

“We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.

Key Points: 
  • “We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.
  • Last fall, QN-01 demonstrated a superior pharmacokinetic profile compared to existing nicotine replacement therapies in our first-in-human Phase 1 clinical trial.
  • We plan to submit our IND and CTA to the regulatory bodies and look forward to commencing our Phase 1/2 clinical study this year.
  • He also served a three-year term on the Board of the Society for Research on Nicotine and Tobacco.

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Retrieved on: 
Tuesday, April 9, 2024
Cardiology, Biotechnology, Technology, Health, General Health, Pharmaceutical, Health Technology, Other Technology, Medical Devices, Artificial Intelligence, Genetics, Diagnosis, Exponential, Cardio, Genomics, Cardiovascular disease, Growth, Entrepreneurship, Partnership, Risk, Patient, Artificial intelligence, Splenic infarction, Death, CHD, Medicine, Concierge medicine, Epigenomics, Moyamoya disease, USD, Medical device

As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.

Key Points: 
  • As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.
  • Concierge practices such as Exponential Health are leading the way in adopting epigenetic cardiovascular solutions.
  • "We are thrilled to partner with Dr. Baer and Exponential Health," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.
  • Integrating Cardio Diagnostics' advanced tests into Exponential Health's offerings is a proactive step toward mitigating this global health challenge.

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Internal medicine, Incretin, Obesity, AstraZeneca, Novo Nordisk, Cardiology, University college, Patient, DSM-IV codes, Weight loss, NAMS, Doctor of Philosophy, MD, Biology, PPD, Inc., Book, Ageing, Pharmaceutical industry

BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors.

Key Points: 
  • BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors.
  • "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs.
  • "I'm excited to join the board of BioAge at this pivotal juncture, as the company progresses azelaprag into Phase 2 trials in obesity," said Davidson.
  • I look forward to working with the team to bring this promising therapy to patients in need."

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

Retrieved on: 
Tuesday, April 9, 2024
Health, Surgery, Genetics, Managed Care, General Health, Cardiology, Biotechnology, Patient, International Society, Caregiver, White, Transplant, Columbia University, University, University of Colorado, Lung transplantation, Heart transplantation, Abstract, Lung, Heart, NYU Langone Health, Stanford University, University Health Network, MAS, Loyola University, Medical device

CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.

Key Points: 
  • CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.
  • This includes AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung, and AiCAV (in development); featured in over 25 oral presentations, posters, and two symposia.
  • These presentations will highlight real-world applications driving advancements in heart and lung transplantation.
  • “We are proud to have a leading presence once again at this pivotal heart and lung transplant meeting.

United States Cardiovascular Devices Market, Size, Share, Forecast 2024-2030 Featuring Abbott Laboratories, Boston Scientific, Edwards Lifesciences, Cardinal Health, Medtronic, GE, J&J, & Siemens - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2024
Health, Medical Devices, Cardiology, Hospital, Cardiac catheterization, Disease, American Heart Association, Stent, Cardiovascular disease, Coronary artery disease, Prevalence, Biotechnology, CVD, ECG, Incidence, Diabetes, Electrocardiography, Public, Research, Mortality, Insight, Death, Risk, Arrhythmia, Diagnosis, Heart failure, CAD, Medical device

Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.

Key Points: 
  • Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.
  • Technology is pivotal in employing growth in the United States cardiovascular devices market.
  • Numerous market players actively enforce strategic tasks, propelling an increase in the United States cardiovascular devices market.
  • In the United States cardiovascular devices market, diagnostics and monitoring devices have a significant presence
    The United States cardiovascular device market is broken up by device type into Diagnostics and Monitoring Devices and Therapeutic and Surgical Devices.

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Retrieved on: 
Monday, April 8, 2024
Research, FDA, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, JAMA, American Medical Association, Cardiovascular disease, Serum, Patient, Journal, RNA, MD, Therapy, Moyamoya disease, Safety, Small RNA, APOLLO, ASCVD, Pharmaceutical industry

“Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.

Key Points: 
  • “Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.
  • Results from the single ascending dose portion of the trial in healthy participants were previously published in the April 2022 issue of JAMA, linked here .
  • Secondary outcomes included the serum levels of zerlasiran and effects on Lp(a) serum concentrations.
  • Zerlasiran is currently being evaluated in the ALPACAR-360 phase 2 study in subjects with baseline Lp(a) levels at or over 125 nmol/L at high risk of ASCVD events.

LIB Therapeutics Announces Positive Results from LIBerate-HR Study: A 52-Week, Placebo-Controlled Registration-Enabling Trial of Lerodalcibep at Late-Breaking Session at American College of Cardiology 2024

Retrieved on: 
Monday, April 8, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Week, Temperature, Cardiovascular disease, PCSK9, CVD, ADAS, FH, Patient, Travel, Female, Refrigeration, OLE, MBBS, Marketing, European Medicines Agency, American College, Therapy, Liberation, ITT, Safety, Food, ACC, Apolipoprotein B, Apolipoprotein, Pharmaceutical industry

Patients were randomized 2:1 to a single 300 mg (1.2 mL subcutaneous) once-monthly dose of Lerodalcibep or placebo for 52 weeks.

Key Points: 
  • Patients were randomized 2:1 to a single 300 mg (1.2 mL subcutaneous) once-monthly dose of Lerodalcibep or placebo for 52 weeks.
  • Of 478 participants in the base LIBerate-HeFH trial, 421 (88%) continued into the OLE trial: 281 patients on Lerodalcibep and 140 on placebo.
  • All participants received open-label Lerodalcibep 300 mg in a subcutaneous 1.2 mL once-monthly dose starting immediately upon completion of the base trial.
  • After 48 weeks of OLE treatment, mean % LDL-C reductions with Lerodalcibep from baseline in the base trial was 48.5% (ITT population).